Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A0B65S3
Fri, 07.01.2022
PAION AG
PAION ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED FUTURE ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
Aachen (Germany), 07 January 2022 - Today, PAION AG, a specialty pharma company (FSE:PA8), and Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, a wholly-owned subsidiary of Humanwell Health [ … ]
Fri, 31.12.2021
PAION AG
PAION SUBMITS EXTENSION APPLICATION OF MARKETING AUTHORIZATION FOR REMIMAZOLAM IN THE INDICATION GENERAL ANESTHESIA TO THE EUROPEAN MEDICINES AGENCY
Aachen (Germany), 31 December 2021 - The Specialty Pharma Company PAION AG (FSE: PA8) today announces that PAION has submitted an extension application to the Marketing Authorization for remimazolam [ … ]
Wed, 10.11.2021
PAION AG
PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST NINE MONTHS OF 2021
- Transformation into commercial specialty pharma company following expansion of European product portfolio; angiotensin II (GIAPREZA(R)) and eravacycline (XERAVA(R)) successfully launched in Q3 2021
- PAION launches remimazolam (Byfavo(R)) in the UK and the Netherland [ … ]
Thu, 16.09.2021
PAION AG
PAION AG ANNOUNCES INITIATION OF PIVOTAL STUDY OF REMIMAZOLAM (BYFAVO(R)) IN PEDIATRIC PROCEDURAL SEDATION
Aachen (Germany), 16 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) announces together with Acacia Pharma (Acacia), remimazolam licensee for the U.S., the initiation of [ … ]
Thu, 02.09.2021
PAION AG
PAION SIGNS EXCLUSIVE UK SUPPLY AND DISTRIBUTION AGREEMENT WITH CLINIGEN
Aachen (Germany), 02 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) today announces that PAION has signed an exclusive partnership agreement with Clinigen for the supply and distribution of its products [ … ]
Wed, 01.09.2021
PAION AG
PAION LAUNCHES XERAVA(R) (ERAVACYCLINE) FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN ADULTS IN THE NETHERLANDS
- Providing broad-spectrum coverage against bacterial pathogens
- XERAVA(R) is the third product launched by PAION in Europe
Aachen (Germany), 01 September 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A [ … ]
Tue, 31.08.2021
PAION AG
PAION AG: HANA PHARM RECEIVES MARKET APPROVAL FOR BYFAVO (REMIMAZOLAM) IN PROCEDURAL SEDATION IN SOUTH KOREA
- Fully-fledged entry into the endoscopy market by adding an indication for 'induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less'
- Use expanded to various surgeries, with 'Byfavo 50m [ … ]
Mon, 23.08.2021
PAION AG
PAION AG REPORTS FINANCIAL RESULTS FOR THE FIRST HALF-YEAR 2021
- Remimazolam partner activities: Market launches in the U.S. and South Korea, total product sales of licensees of EUR 2.7 million.
- EU market approval for remimazolam (Byfavo(R)) in procedural sedation; approval and product launch of Byfavo(R) in UK
- Expansion of European produc [ … ]
Mon, 16.08.2021
PAION AG
PAION LAUNCHES BYFAVO(R) (REMIMAZOLAM) IN THE UK FOR PROCEDURAL SEDATION
- Millions of procedures take place in the UK annually such as colonoscopies and bronchoscopies that require the use of procedural sedation
- Byfavo(R) is the first product developed by PAION approved and launched in Europe
Aachen (Germany), 16 August 2021 - The Specialty [ … ]
Fri, 16.07.2021
PAION AG
PAION LAUNCHES GIAPREZA(R) (ANGIOTENSIN II) FOR THE TREATMENT OF REFRACTORY HYPOTENSION IN ADULTS WITH SEPTIC OR OTHER DISTRIBUTIVE SHOCK IN GERMANY
- GIAPREZA(R) is the first product launched by PAION in Europe
Aachen (Germany), 16 July 2021 - The Specialty Pharma Company PAION AG (PA8; ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard) [ … ]